PFMOSF
MTNB icon

Philadelphia Financial Management of San Francisco’s Matinas BioPharma MTNB Stock Holding History

Philadelphia Financial Management of San Francisco’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,817
Closed -$1.01M – 67
2020
Q4 		$1.01M Buy
+14,817
New +$686K 0.26% 61

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Philadelphia Financial Management of San Francisco's MTNB Position: Q1 2021 in Review

Philadelphia Financial Management of San Francisco sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 14,817 shares — an estimated $1.01M sold.

Philadelphia Financial Management of San Francisco first reported a position in MTNB in Q4 2020 and held it in 1 quarter. The position peaked at $1.01M in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

  • Philadelphia Financial Management of San Francisco reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
  • Philadelphia Financial Management of San Francisco sold 14,817 Matinas BioPharma shares in Q1 2021, an estimated $1.01M.
  • Philadelphia Financial Management of San Francisco first reported a position in Matinas BioPharma in Q4 2020 and held it in 1 quarter.
  • Philadelphia Financial Management of San Francisco's Matinas BioPharma position peaked at $1.01M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on Philadelphia Financial Management of San Francisco's 13F filing for Q1 2021, filed 17 May 2021.